Cancer Advisor

Pancreatic cancer has long been one of the most feared diagnoses in oncology—aggressive, late-detected, and historically resistant to treatment. But 2026 marks a potential turning point. A recent report by The Washington Post highlights early but meaningful survival improvements in clinical trials, signaling a new era for one of the deadliest cancers. A convergence of  KRAS-targeted therapies, immunotherapy, personalized vaccines, and metabolic strategies—including repurposed drugs like Ivermectin and Mebendazole—is reshaping the treatment landscape.  Reports highlighted by The Washington Post and emerging clinical trial data suggest that pancreatic cancer may be entering its first true era of therapeutic progress. This pillar page delivers a  deep, evidence-based, clinically grounded analysis  of: What’s actually changed in 2026 The role of KRAS inhibitors and immunotherapy The rise of targeted metabolic therapy Where repurposed drugs fit (and where they don’t) Sur...

Abstract Background:  Stage IV pancreatic ductal adenocarcinoma (PDAC) lacking actionable mutations has limited treatment options, with median overall survival (mOS) of 9–11 months using standard chemotherapy. Repurposed drugs (ivermectin, mebendazole) and hyperthermia show preclinical promise. This in silico randomized controlled trial (RCT) evaluates an integrative protocol combining ivermectin, mebendazole, hyperthermia, supplements, and lifestyle interventions versus standard-of-care (SOC) NALIRIFOX chemotherapy in non-BRCA-mutated stage IV PDAC. Methods:  A simulated two-arm RCT enrolled 200 patients with non-BRCA-mutated stage IV PDAC, randomized 1:1 to an experimental arm (ivermectin 1 mg/kg/day 3 days/week, mebendazole 500 mg twice daily, localized hyperthermia 42–43°C 3 sessions/week, supplements [vitamin C, vitamin D, curcumin, berberine], ketogenic diet, intermittent fasting, pancreatic enzymes) or control arm (NALIRIFOX). Primary endpoint was 12-month overall surv...

Introduction: The Shift From Description to Prediction For the past two decades, cancer research has been dominated by one central idea: If we understand the genetic mutations driving a tumor, we can target them precisely. This gave rise to precision oncology —a paradigm built on genomic sequencing, biomarker testing, and targeted therapies. But a hard truth has emerged: Patients with identical mutations often have wildly different outcomes . This inconsistency has fueled the rise of predictive oncology —a more advanced approach that aims to forecast treatment response before therapy begins, powered by Artificial intelligence and multi-layered biological data. 1. What Is Precision Oncology? Precision oncology focuses on matching therapies to tumor biology . Core principle: Treat the mutation, not just the tumor location. According to the National Cancer Institute, precision medicine uses genetic or molecular profiling to guide therapy selection, improving outcomes in selected patient ...

Abstract Cancer remains a leading cause of mortality worldwide, with incidence rates projected to rise significantly in the coming decades. While advances in treatment have modestly improved survival, prevention through modifiable risk factors remains underemphasized. This review synthesizes current evidence on the role of diet, lifestyle, and dietary supplements in cancer prevention, drawing on systematic reviews, meta-analyses, and major guideline recommendations. The I-PREVENT CANCER protocol is introduced as a practical, evidence-based framework for reducing cancer risk. Introduction Despite trillions spent on cancer research , cancer still kills around 10 million people a year and is a leading cause of death globally. The incidence of common cancers such as breast, lung, and colon cancer is expected to increase by over 75% between 2022 and 2050.  While treatment advances offer incremental improvements in survival, prevention strategies—particularly those related to diet and l...